Antigen-Based Immune Therapies for Type 1 Diabetes
Author Information
Author(s): Slobodan Culina, Christian Boitard, Roberto Mallone
Primary Institution: INSERM, U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, Paris, France
Hypothesis
Can antigen-based immune therapies effectively target the autoimmune mechanisms underlying Type 1 diabetes?
Conclusion
Antigen-based therapies show promise in targeting the autoimmune response in Type 1 diabetes, but their effectiveness varies significantly between preclinical models and human trials.
Supporting Evidence
- Different antigen formulations are being considered, such as proteins or peptides, DNA plasmids, and cell-based agents.
- Studies in the NOD mouse suggest that the majority of β-cell mass is destroyed by the time of diabetes onset.
- Insulin and GAD have reached the stage of clinical trials as antigen-based therapies.
Takeaway
This study looks at how certain treatments might help people with Type 1 diabetes by targeting the immune system, but results in mice don't always work the same way in humans.
Methodology
The study reviews various antigen-based therapies and their translation from mouse models to human clinical trials.
Potential Biases
Potential biases may arise from the reliance on preclinical models that do not fully represent human disease.
Limitations
The translation of findings from mouse models to humans is complicated by significant biological differences and the timing of interventions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website